What Your Whoop Score Is Not Telling You About Your Heart

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Heart rate variability is the most clinically interesting metric the wearable industry has made accessible to the general public. It is also the metric most likely to be misread, misused, and oversold into territory the clinical evidence does not support.

What HRV Measures

Heart rate variability is the variation in the time interval between successive heartbeats. A heart beating at 60 beats per minute is not producing one beat every exactly 1,000 milliseconds. In a healthy autonomic nervous system, those intervals vary slightly from beat to beat. The variation is driven by the balance between the sympathetic and parasympathetic branches of the autonomic nervous system.

Sympathetic influence: regularizes and accelerates the heartbeat. Stress, exercise, and threat activates the sympathetic branch.

Parasympathetic (vagal) influence: slows and variabilizes the beat. Rest, recovery, and safety activates the parasympathetic branch.

Higher HRV reflects stronger parasympathetic tone. Lower HRV reflects sympathetic dominance. The metric is, at its core, a measure of how much vagal tone is present in your cardiovascular system at the moment of measurement.

This is why HRV falls during illness, overtraining, acute stress, alcohol consumption, and sleep deprivation, and rises with aerobic fitness, rest, and recovery. The metric is tracking the autonomic balance, not a single variable.

HRV Metrics: What the Numbers Actually Mean

The clinical literature does not use a single HRV number. Several metrics appear across published studies, each capturing a different aspect of autonomic function. Knowing which number your device reports, and which number the clinical research used, prevents you from drawing conclusions that do not apply.

SDNN (standard deviation of all normal-to-normal R-R intervals) captures total HRV across all time scales. It reflects both sympathetic and parasympathetic contributions to beat-to-beat variation. SDNN is the most widely validated metric in clinical prognostic studies. The ATRAMI trial and the Framingham analyses both relied on SDNN. A 24-hour SDNN below 50 ms is associated with substantially elevated cardiovascular mortality risk in the post-MI and general population literature. This is the number your cardiologist looks at on a Holter report.

RMSSD (root mean square of successive differences between adjacent R-R intervals) captures high-frequency, vagally-driven variability. It reflects short-term parasympathetic tone rather than total autonomic variability. RMSSD is what most consumer wearables report because it can be estimated from short recordings, is less sensitive to respiratory pattern during measurement, and tracks recovery and sleep quality on a day-to-day basis with reasonable sensitivity.

pNN50 (percentage of successive beat pairs differing by more than 50 ms) is a related high-frequency metric derived from the same underlying signal as RMSSD. Both reflect vagal activity. The two tend to correlate closely.

Frequency domain metrics come from spectral analysis of R-R interval data. Low-frequency power (LF, 0.04 to 0.15 Hz) reflects a mixture of sympathetic and parasympathetic activity. High-frequency power (HF, 0.15 to 0.4 Hz) reflects pure vagal activity tied to the respiratory cycle. The LF/HF ratio has been proposed as a measure of autonomic balance, but it remains controversial in the clinical literature because the LF band does not cleanly separate sympathetic from parasympathetic contributions.

For practical purposes: RMSSD from your wearable tracks day-to-day vagal tone and training recovery. SDNN from a 24-hour Holter is what carries weight in cardiovascular risk stratification. These are different signals from the same underlying biology. A wearable RMSSD of 55 and a clinical SDNN of 55 are not the same measurement, not measured the same way, and not directly comparable to each other.

The Clinical Evidence

Post-Myocardial Infarction Populations

The strongest clinical evidence for HRV as a prognostic marker comes from post-MI populations. The ATRAMI study, published in Lancet 1998, followed 1,284 patients after myocardial infarction and found that low HRV (SDNN below 70 ms) was an independent predictor of cardiac mortality at 21 months, with a relative risk of 3.2 after adjustment for clinical variables. 5 / Solid

This is the signal the clinical cardiologist uses when reviewing a post-MI patient’s 24-hour Holter: low time-domain HRV is a marker of increased autonomic vulnerability to fatal arrhythmia. The mechanism is reduced vagal protection against ventricular arrhythmia in the peri-infarct period.

General Population

The evidence in apparently healthy populations is more modest but directionally consistent. The Tsuji analysis of the Framingham cohort found that reduced SDNN (the standard deviation of all R-R intervals) independently predicted cardiovascular events in the general population after adjustment for traditional risk factors. 4 / Promising (Tsuji et al. 1996, Circulation)

Subsequent meta-analyses have confirmed the directional association. Lower resting HRV in healthy adults predicts adverse cardiovascular outcomes. The magnitude of the association in healthy populations is smaller than in post-MI populations, but it is consistent across studies. 4 / Promising

The Autonomic Mechanism

The mechanistic rationale for why low vagal tone predicts cardiovascular events:

The vagus nerve provides direct anti-arrhythmic protection to the heart through acetylcholine release and direct hyperpolarization of the sinoatrial and atrioventricular nodes. Reduced vagal tone removes this protection. The sympathetically dominated heart is more susceptible to ventricular arrhythmia under conditions of ischemia or stress.

Vagal tone also has anti-inflammatory effects through the cholinergic anti-inflammatory pathway. Reduced vagal tone permits higher systemic inflammatory activity, which is independently atherogenic.

What Consumer Wearables Actually Measure

Consumer wearables (Whoop, Oura, Apple Watch, Garmin) measure HRV through photoplethysmography (PPG), a light-based sensor on the wrist or finger that detects blood volume changes rather than the electrical signal of the heart. The R-R interval calculation from PPG is an approximation, validated against ECG for some conditions but less accurate during artifact, motion, or conditions that degrade the PPG signal.

Critical comparability problem: Different devices use different algorithms, different measurement windows, and different frequency domain calculations. The RMSSD metric most commonly reported by wearables (root mean square of successive R-R differences) emphasizes high-frequency HRV driven primarily by respiratory variability. SDNN, the standard clinical metric, reflects total HRV across all frequencies.

A Whoop HRV of 60 cannot be directly compared to an Oura HRV of 60. They are not measuring the same thing, in the same way, with the same precision.

This means: do not compare your HRV to someone else on a different device. Compare your HRV only to your own historical baseline on the same device.

HRV and Diabetes: A Specific Risk Signal

Autonomic neuropathy from diabetes produces some of the most dramatic HRV depression seen outside the post-MI population. When both sympathetic and parasympathetic nerve fibers are progressively damaged by chronic hyperglycemia, the heart loses its normal beat-to-beat variability. The result is a characteristically low, fixed heart rate with minimal variation, a pattern called cardiac autonomic neuropathy (CAN). This is not a subtle signal. SDNN values in patients with established diabetic CAN can fall well below the thresholds that predict mortality risk in post-MI populations.

The Fremantle Diabetes Study and the EURODIAB Complications Study both found that low HRV in diabetic patients independently predicted cardiovascular mortality, separate from other known risk factors. 4 / Promising The EURODIAB data in particular showed that cardiovascular autonomic neuropathy roughly doubles the risk of mortality over a 10-year follow-up.

Here is why this matters for a man who thinks he is fine: autonomic neuropathy begins before a diabetes diagnosis. Insulin resistance and pre-diabetes, states that produce no obvious symptoms and that most men do not screen for, can cause subclinical autonomic damage detectable through HRV before clinical diabetes is established. A man whose resting HRV is declining steadily over months, with no clear fitness, training, or stress explanation, may be looking at an early metabolic signal rather than a recovery problem.

This is a specific clinical implication: a declining HRV trend without an obvious behavioral cause should prompt a fasting glucose and fasting insulin, not just a conversation about sleep and training load. The wearable is not telling you that you are overtrained. It may be telling you something more medically specific.

HRV and Sleep: The Nocturnal Signal

The clinical HRV literature distinguishes between daytime and nocturnal HRV, and the distinction matters. In healthy individuals, HRV is substantially higher during sleep than during waking hours because parasympathetic tone normally dominates the sleeping cardiovascular system. The heart rate slows, vagal activity increases, and beat-to-beat variability rises. This nocturnal parasympathetic dominance is a feature of healthy autonomic function.

Obstructive sleep apnea (OSA) disrupts this pattern directly. Each apneic episode and subsequent arousal triggers a sympathetic spike, a burst of adrenergic activity that pulls the autonomic system out of its resting vagal state. Repeated hundreds of times per night, these arousals fragment the normal nocturnal HRV architecture. Studies using 24-hour Holter recordings show that OSA patients have blunted nocturnal HRV elevation and higher 24-hour mean heart rate compared to controls matched for age and fitness. 4 / Promising

This creates an important interpretive issue for wearable users. Devices that measure HRV primarily during sleep, including Oura and Whoop, may actually be capturing a signal that reflects sleep-disordered breathing rather than training recovery. A man who is fit, trains consistently, manages stress well, and still sees persistently low nighttime HRV readings may have OSA as the underlying driver. He does not know he has it because OSA in middle-aged men is frequently asymptomatic or attributed to normal snoring and daytime fatigue that seems explainable by work and schedule.

If your nocturnal HRV trend is consistently low without a clear training or behavioral explanation, the question to ask clinically is not about recovery protocols. It is whether your sleep architecture is intact. A home sleep study or formal polysomnography is more appropriate than a new breathing protocol.

What the Wellness Industry Oversells

The consumer HRV market has produced significant content asserting that optimizing your HRV score through breathing protocols, cold exposure, supplements, and other interventions reduces cardiovascular risk. The evidence for these claims requires honest grading.

Slow paced breathing (6 breaths per minute, coherent breathing): Acutely increases HRV through respiratory sinus arrhythmia. The acute effect is real and reproducible. Long-term cardiovascular event reduction from breathing practice: not established in clinical trials. 3 / Early

Cold water immersion: Acutely increases parasympathetic tone and transiently elevates HRV. Chronic cardiovascular benefit: not established. 2 / Theoretical

Adaptogens and supplements marketed for HRV: No clinical trial evidence for cardiovascular outcomes or sustained HRV improvement. 2 / Theoretical

Aerobic fitness: This is the strongest and most consistently documented driver of resting HRV improvement. Regular aerobic exercise increases vagal tone, improves SDNN and RMSSD, and has cardiovascular outcome benefits documented independently of HRV. 5 / Solid

The hierarchy is important: fitness training works. Breathing exercises have modest acute effects. Supplements have no meaningful evidence. The marketing order in the wearable ecosystem is reversed.

What Actually Moves HRV in the Long Term

If the goal is to improve resting HRV in a way that reflects genuine cardiovascular benefit rather than a temporarily elevated morning reading, the clinical evidence gives a clear hierarchy. Not everything marketed as an HRV intervention has the same backing.

Aerobic fitness training is the most consistently documented intervention. Multiple randomized controlled trials show that sustained aerobic exercise programs, typically 12 weeks or longer at moderate to vigorous intensity, produce significant improvements in SDNN and RMSSD. The effect is mediated by increased cardiac vagal tone at rest and is not simply a training artifact. Cardiovascular outcome benefits from aerobic exercise are independently established, so the HRV improvement here tracks with real-world risk reduction. 5 / Solid

Treating obstructive sleep apnea with CPAP produces significant HRV improvement in randomized data. Kohler et al. (2008, Sleep) showed measurable increases in nocturnal HRV in OSA patients randomized to CPAP versus sham treatment, with the effect size correlating with degree of apnea severity at baseline. This makes mechanistic sense: removing the repeated nocturnal sympathetic surges allows the parasympathetic system to function normally during sleep. 4 / Promising

Blood pressure control improves autonomic function and HRV in hypertensive patients. Elevated blood pressure is independently associated with reduced HRV, and effective antihypertensive treatment in randomized trials produces modest but consistent HRV improvements alongside the primary outcome benefits.

Alcohol reduction produces measurable HRV improvement. Even moderate alcohol consumption suppresses vagal tone acutely and, with habitual use, reduces resting HRV. Men who drink regularly and then reduce intake reliably show HRV increases on wearable tracking. This is one of the clearest behavioral signals the devices actually capture accurately.

Slow-paced breathing produces acute HRV increases through respiratory sinus arrhythmia. The physiological mechanism is real. Whether sustained breathing practice translates into reduced cardiovascular event rates over years is not established in outcome trials. The effect is real during the practice; whether it persists in the resting state without practice, or whether it changes hard outcomes, remains unresolved. 3 / Early

The Three Things Worth Knowing

The 90-day trend matters more than any single reading. A declining HRV trend over three months on the same device, in the absence of obvious explanatory illness or training change, is a signal worth investigating clinically. It suggests the autonomic system is not recovering from the demands placed on it.

The day-to-day variability is noise. An individual morning reading can be affected by alcohol the night before, poor sleep position, stress the previous day, or minor illness. Single readings do not carry clinical significance.

HRV is a proxy, not a diagnosis. Declining HRV may reflect overtraining, unresolved chronic stress, early illness, sleep disorder, or subclinical cardiac dysfunction. It warrants a clinical conversation, not a self-diagnostic decision.

Three Actions

1. Look at your 90-day HRV trend on your wearable, not this morning’s reading. If it is declining across three months without an obvious behavioral explanation, bring that trend to your physician.

2. Identify the highest-evidence intervention for your HRV: consistent aerobic exercise. Nothing in the supplement or consumer wellness market approaches the cardiovascular and autonomic benefit of 150 minutes per week of moderate-intensity exercise.

3. If your physician wants clinical HRV data, the tool is a 24-hour Holter monitor, not your wearable. Ask for one if clinically indicated. It measures SDNN and RMSSD in the validated clinical format and with ECG-level accuracy.

This paper is educational and does not constitute medical advice. Discuss your individual clinical situation with your physician.